Login to Your Account



Voyager left space to craft success in PD as Genzyme option rocket doesn't fire

By Randy Osborne
Staff Writer

Tuesday, October 31, 2017

Voyager Therapeutics Inc. CEO Steven Paul said his firm is "pleased to retain – and gain, if you will – worldwide rights to this [Parkinson's disease (PD)] program" from Sanofi SA. "We believe it's a winner."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription